|Home | About | Journals | Submit | Contact Us | Français|
This systematic review is an update of evidence since the 2002 U.S. Preventive Services Task Force (USPSTF) recommendation on breast cancer screening.
To determine the effectiveness of mammography screening in decreasing breast cancer mortality among average-risk women age 40 to 49 and 70 and older; the effectiveness of clinical breast examination (CBE) and breast self examination (BSE); and harms of screening.
Cochrane Controlled Trials Registry and Database of Systematic Reviews (4th Quarter 2008), MEDLINE® (January 2001 to December 2008), reference lists, and Web of Science® for published studies; Breast Cancer Surveillance Consortium for screening mammography data.
Randomized controlled trials with breast cancer mortality outcomes for screening effectiveness; multiple study designs and data sources for harms.
Investigators abstracted relevant data and rated study quality using established criteria.
Mammography screening reduces breast cancer mortality by 15% for women age 39 to 49 (relative risk 0.85; 95% CrI 0.75 to 0.96; 8 trials); data are lacking for age ≥70. Radiation exposure from mammography is low. Patient adverse experiences are common, transient, and do not impact screening practices. Estimates of overdiagnosis vary from 1% to 10%. Younger women have more false positive mammograms and additional imaging, but fewer biopsies than older women. Trials of CBE are ongoing; for BSE, trials showed no reductions in mortality but increased benign biopsies.
Studies of older women, digital mammography, and MRI are lacking.
Mammography screening reduces breast cancer mortality for women age 39 to 69; data are insufficient for older women. False positive mammograms and additional imaging are common. No benefit has been shown for CBE or BSE.
This systematic evidence review is an update of evidence for the U.S. Preventive Services Task Force (USPSTF) recommendation on breast cancer screening for average-risk women (1). In 2002, based on results of a prior review (2, 3), the USPSTF recommended mammography screening, with or without clinical breast examination (CBE), every 1 to 2 years for women age 40 years and older. They concluded that the evidence was insufficient to recommend for or against routine CBE alone, and insufficient to recommend for or against teaching or performing routine breast self-examination (BSE).
Breast cancer is the most frequently diagnosed non-cutaneous cancer and the second leading cause of cancer deaths among women in the United States (4). In 2008, an estimated 182,460 cases of invasive and 67,770 cases of noninvasive breast cancer were diagnosed, and 40,480 women died of breast cancer (4). Incidence increases with age, and the probability of a woman developing breast cancer in her forties is 1 in 69, in her fifties 1 in 38, and in her sixties 1 in 27 (5). Data suggest that incidence has stabilized in recent years (6-8), and mortality has decreased since 1990 (9, 10) due to multiple factors including screening (11). In 2005, 68% of women age 40 to 65 had a screening mammogram within the prior 2 years in the United States (4).
Breast cancer has a known asymptomatic phase that can be detected with mammography. Mammography screening is sensitive (77% to 95%), specific (94% to 97%), and acceptable to most women (2). It is performed using either plain film or digital technologies, although the shift to digital is ongoing. Contrast enhanced magnetic resonance imaging (MRI) has traditionally been used to evaluate women already diagnosed with breast cancer. Recommendations for its use in screening pertain to certain high-risk groups only (12). If a woman has an abnormal mammographic finding on screening, or a concerning finding on physical examination, additional imaging and biopsy may be recommended. Additional imaging may consist of a diagnostic mammogram or a mammogram done with additional or special views, a targeted breast ultrasound, or breast MRI (13, 14). Additional imaging may help classify the lesion as a benign or suspicious finding in order to determine the need for biopsy. Biopsy techniques vary in the level of invasiveness and amount of tissue acquired, impacting their yield and patient experience.
This review focuses on new studies and evidence gaps that were unresolved at the time of the 2002 USPSTF recommendation. These include the effectiveness of mammography screening in decreasing breast cancer mortality among average-risk women age 40 to 49 and 70 and older; the effectiveness of CBE and BSE in decreasing breast cancer mortality among women of any age; and the magnitude of harms of screening with mammography, CBE, and BSE.
Key questions guiding this update were developed by the USPSTF and Agency for Healthcare Research and Quality (AHRQ). Investigators created an analytic framework incorporating the key questions and outlining the patient population, interventions, outcomes, and harms of the screening process (Appendix Figure 1). The target population includes women without pre-existing breast cancer and not considered high-risk for breast cancer based on extensive family history of breast or ovarian cancer or other personal risk factors such as abnormal breast pathology or deleterious genetic mutations. Harms include radiation exposure, pain during procedures, patient anxiety and other psychological responses, consequences of false positive and false negative tests, and overdiagnosis. Overdiagnosis refers to diagnosing women with invasive or noninvasive breast cancer who had abnormal lesions that were unlikely to become clinically evident during their lifetimes in the absence of screening (15). Overdiagnosis may have more impact on women with shorter life expectancies because of age or comorbidities.
We searched the Cochrane Controlled Trials Registry and Cochrane Database of Systematic Reviews (through 4th Quarter 2008) and MEDLINE® database (January 1, 2001 to December 1, 2008) for relevant studies and meta-analyses (16). We also conducted secondary referencing by manually reviewing reference lists of key papers and searching citations using Web of Science® (17). Search results are indicated in Appendix Figure 2.
We selected studies based on inclusion and exclusion criteria developed for each key question (16). To determine the effectiveness of screening, we included randomized controlled trials and updates to previously published trials of screening with mammography (film, digital), MRI, CBE, or BSE with breast cancer mortality outcomes published since 2001. One trial was translated to English from Russian for this update (18). Meta-analyses that included studies with mortality data were also reviewed. Studies other than controlled trials and systematic reviews or without breast cancer mortality as an outcome were excluded.
We determined harms of screening using evidence from multiple study designs and data sources. For mammography, we focused our searches on recently published systematic reviews and meta-analyses of the harms listed above. We also conducted specific searches for primary studies published more recently than the included systematic reviews and meta-analyses. In addition, we evaluated data from the Breast Cancer Surveillance Consortium (BCSC), a collaborative network of 5 mammography registries and 2 affiliated sites with linkages to pathology and/or tumor registries across the United States, sponsored by the National Cancer Institute (19, 20). These data draw from community populations representing a national demographic sample, and may be more applicable to current practice in the United States than other published sources. Data include a mix of film and digital mammograms. For harms of CBE and BSE, we reviewed screening trials of these procedures that reported potential adverse effects, utilized recently published systematic reviews, and conducted focused searches.
We abstracted details about the patient population, study design, analysis, follow-up, and results. Using predefined criteria developed by the USPSTF (21), two investigators rated the quality of each study as “Good,” “Fair,” or “Poor,” resolving discrepancies by consensus. We included only systematic reviews rated good quality in the report and randomized controlled trials rated fair or good quality in the meta-analysis.
We updated the 2002 meta-analysis to include new findings from published trials of mammography screening compared to controls for women age 40 to 49 that reported relative risk reduction in breast cancer mortality. We conducted similar updates for other age groups for context. Breast cancer mortality results from trials were used to estimate the pooled relative risk. Estimates were calculated from a random effects model under the Bayesian data analytic framework using the RBugs package in R (22, 23); the same model as the previous report (2). Additional details are provided in the Appendix. We used funnel plots to assess publication bias and L'Abbé plots to assess heterogeneity.
Data from 600,830 women age 40 years and older undergoing routine mammography screening during 2000 to 2005 at the BCSC sites were obtained from the BCSC Statistical Coordinating Center and stratified by age in decades. Routine screening was defined as having at least one prior mammogram within the previous 2 years, consistent with current USPSTF recommendations. For women with multiple mammograms during the study period, one mammogram was randomly selected to include in the calculations. These data constitute a selected subset of BCSC data intended to represent the experience of a cohort of regularly screened women without preexisting breast cancer or abnormal physical findings.
Variables include the numbers of positive and negative mammograms and, of these, the numbers of true negative and false negative results based on follow-up data within one year of mammography screening. A positive mammogram was defined according to standardized terminology and assessments of the American College of Radiology Breast Imaging Reporting and Data System (BI-RADS) manual used by the BCSC (24). These include needs additional evaluation (category 0), probably benign with a recommendation for immediate follow-up (category 3), suspicious (category 4), or highly suggestive of malignancy (category 5) (25). For women with positive screening mammograms, additional data include the number undergoing additional imaging, number undergoing biopsy, and diagnoses including invasive cancer, ductal carcinoma in situ (DCIS), and negative results. Additional imaging procedures and biopsies performed within 60 days of the screening mammogram were considered related to screening. From these data, we calculated age-specific rates (numbers per 1000 per round) of invasive breast cancer, DCIS, false positive and false negative mammograms, additional imaging, and biopsies. True positive and negative mammograms were based on invasive and noninvasive cancer diagnosis. Rates of additional imaging and rates of biopsies may be underestimated due to incomplete capture of these exams by the BCSC. A sensitivity analysis of missing values is presented in the full evidence review (16), although this does not include records that were unavailable to the BCSC.
The AHRQ funded this work, provided project oversight, developed key questions in conjunction with USPSTF members, and assisted with internal and external review of the draft, but had no additional role in the design, conduct, or reporting of the review. The draft was reviewed by 15 external experts not affiliated with the USPSTF.
The 2002 evidence review for the USPSTF included a meta-analysis (2) of 7 randomized trials of mammography screening rated fair quality (26-28). Since then, a randomized trial from the United Kingdom evaluating the effect of mammography screening specifically in women age 40 to 49 years has been published (29), as well as updated data from a previously reported Swedish trial (30). No trials of screening average-risk women specifically evaluating the effectiveness of digital mammography or MRI have been published.
The Age trial included 160,921 women ages 39 to 41 years who were randomly assigned between 1991 to 1997 to screening with annual mammography until age 48 years, or a control group receiving usual care in the United Kingdom (Table 1) (29). After 10.7 years of follow-up, the relative risk for all cause mortality was 0.97 (95% confidence interval [CI] 0.89 to 1.04) and for breast cancer mortality 0.83 (95% CI 0.66 to 1.04) among women in the screened group. Based on the absolute reduction in breast cancer mortality among women invited for screening, the number needed to invite for screening to prevent one death from breast cancer over 10 years was 2,512 (95% CI 1,149 to 13,544). The Age trial met USPSTF criteria for fair rather than good quality because descriptions of contamination of groups were absent and 70% or fewer women attended screening across the trial.
A new publication provides additional data from the Gothenburg trial (Table 1) (30). In this paper, breast cancer mortality rates and risk ratios were calculated using three methods, including a more comprehensive method that considers breast cancer mortality from cancers diagnosed during the follow-up phase of the trial. Using this method for women ages 39 to 49 at trial entry, the relative risk for breast cancer mortality was 0.69 (95% CI 0.45 to 1.05) after 13 years of follow-up, among women in the screened group. (30).
For women age 39 to 49 years, 8 trials provided data for the meta-analysis including 6 from the 2002 meta-analysis (Health Insurance Plan [HIP] of Greater New York (27), Canadian National Breast Screening Study-1 [CNBSS-1] (28), Stockholm (26), Malmo (26), Swedish Two-County [2 trials] (26)), an update of the Gothenburg trial (30), and the new Age trial (29). Combining results, the pooled relative risk for breast cancer mortality for women invited to mammography screening was 0.85 (95% Credible Interval [CrI] 0.75 to 0.96), indicating a 15% reduction in breast cancer mortality in favor of screening (Figure). This corresponds to a number needed to invite for screening to prevent one breast cancer death of 1,904 (95% C rI 929 to 6,378) over multiple screening rounds that varied by trial (2 to 9 rounds), and 11 to 20 years of follow-up. A funnel plot did not indicate the presence of publication bias and an L'Abbé plot did not reveal serious heterogeneity between the studies (16). Results are consistent with the 2002 meta-analysis (relative risk 0.85; 95% CrI 0.73 to 0.99; 7 trials) (2, 3).
Sensitivity analysis that 1) excluded the HIP trial because it was conducted over 30 years ago using outdated technology; 2) excluded the Canadian trial because it enrolled prescreened volunteers rather than unselected populations; and 3) excluded both the HIP and Canadian trials; did not significantly influence the results (16).
Results for women age 70 and older were confined to data from the Swedish Two-County trial (Ostergotland) of women age 70 to 74, precluding meta-analysis. These results indicate a relative risk for breast cancer mortality of 1.12 (95% CI 0.73 to 1.72) (26) based on a more conservative determination of cause of death than prior reports (31, 32). The absolute numbers of deaths were not reported, the number of enrolled women was low (approximately 5,000 in each arm), and the number needed to screen was not estimable.
Meta-analyses of trials for women age 50 to 59 years and 60 to 69 years were performed to compare with results for women age 40 to 49 and over 70 (Table 2). Results are not directly comparable to the 2002 meta-analysis that provided a combined estimate for women age 50 to 74 years (relative risk 0.78; 95% CrI, 0.70 to 0.87; 7 trials) (2).
For women age 50 to 59 years, 6 trials (CNBSS-2 (52), Stockholm (26), Malmo (26), Swedish Two-County [2 trials] (26), Gothenburg (30)) provided a pooled relative risk for breast cancer mortality for women invited to mammography screening of 0.86 (95% CrI 0.75 to 0.99); number needed to invite 1,339 (95% CrI 322 to 7,455). Sensitivity analysis that excluded the Canadian trial resulted in a lower relative risk (0.81; 95% CrI 0.68 to 0.95). For women age 60 to 69 years, 2 trials (Malmo (26) and Swedish Two-County [Ostergotland] (26)) provided a pooled relative risk for breast cancer mortality for women invited to mammography screening of 0.68 (95% CrI 0.54 to 0.87); number needed to invite 377 (95% CrI 230 to 1,050).
No studies directly measure the association between radiation exposure from mammography screening and breast cancer. Most x-rays are considered low dose, low energy radiation with the mean glandular dose of a bilateral 2-view mammogram averaging 7 mGy (33). For women age 40 to 49, yearly mammography screening for one decade with potential additional imaging would expose an individual to approximately 60 mGy, although these levels vary (34). A recent systematic review included various types of studies of radiation exposure, such as radiation therapy, diagnostic radiation, and atomic bomb radiation, as the basis for predicting risk for inducing breast cancers (34). In studies of low dose exposures, associations were inconsistent, while those of high dose exposures indicated increased risk for breast cancer (34). The relative risks in studies of high dose exposures ranged from 1.33 to 11.39 for exposures of 0.3 to 43.4 Gy, and were worse with higher doses of exposure, younger age at exposure, and longer follow-up (34). A more recent case-control study found that women exposed to diagnostic x-rays for screening or monitoring tuberculosis or pneumonia, or therapeutic radiation for a prior cancer, had increased risks for breast cancer (35).
Breast compression is used during mammography to create uniform density, reduce breast thickness, and flatten overlying skin and tissues, contributing to sharper images and reducing radiation dose. This may contribute to discomfort for some women. A recent systematic review of 22 studies of pain and discomfort associated with mammography indicated that many women experience pain during the procedure (ranging from 1% to 77%), but few women would consider this a deterrent from future screening (34). In these studies, pain was associated with the stage of the menstrual cycle, anxiety, and the anticipation of pain (34).
Studies have shown conflicting results about anxiety, distress, and other psychological responses incurred as a result of mammography screening. A systematic review of 54 studies assessed the adverse psychological effects of mammography screening programs (36). Most were cohort studies, and 24 used validated psychological measurement scales to assess the effects of screening. Studies indicated that women who received clear communication of their negative mammogram results had minimal anxiety (36). Results were mixed in studies of women who were recalled for further testing as a result of screening. In several studies, women had persistent anxiety, despite eventual negative results, while some showed only transient anxiety (36). Some studies showed no differences between anxiety levels of women who had initial negative screening mammograms and those who had false positives (36).
A recent systematic review of 23 studies specifically examined the effects of false positive screening mammograms on women over age 40 (37). Included were 9 studies on psychological distress, 11 studies on anxiety, and 6 studies on worry. In these studies, false positive mammograms had no consistent effect on most women's general anxiety and depression, but increased breast cancer specific distress, anxiety, apprehension, and perceived breast cancer risk for some (37).
Published data on false positive and negative mammograms, additional imaging, and biopsies reflecting current practices in the United States are limited. The probability of a false positive screening mammogram was estimated at 0.9% to 6.5% in a meta-analysis of studies of sensitivity and specificity of mammography published 10 years ago (38). The cumulative risk for false positive mammograms has been reported as 21% to 49% after 10 mammograms for women in general (39-41), and up to 56% for women age 40 to 49 years (41). Additional data about mammography test performance indicate that sensitivity, recall rates, and cancer detection rates increase as the months since prior mammography increase, while specificity decreases (42). Few studies evaluate the impact of negative mammogram results. Women stated that they would not delay evaluation of a new abnormal physical finding despite a prior negative mammogram in one survey (43).
Data from the BCSC for regularly screened women based on results from a single screening round indicate that false positive mammograms are common in all age groups, but are most common among women age 40 to 49 (97.8/1000 per screening round) (Table 3). False negative mammograms occur least among women 40 to 49 (1.0/1000 per screening round). Rates of additional imaging are highest among women age 40 to 49 (84.3/1000 per screening round) and decrease with age, while biopsy rates are lowest among women age 40 to 49 (9.3/1000 per screening round) and increase with age. The BCSC results indicate that for every case of invasive breast cancer detected by mammography screening in women age 40 to 49 years, 556 women undergo mammography, 47 additional imaging, and 5 biopsies.
A review of randomized controlled trials of mammography screening compared the cumulative incidence of breast cancer in intervention and control arms to determine the extent of overdiagnosis (44). In the 5 trials in which the control group was not offered screening, the absolute excess cumulative incidence of invasive and in situ breast cancer attributed to overdiagnosis among women undergoing screening mammography ranged from 0.07 to 0.73 per 1,000 women years.
Eight other studies report estimates of overdiagnosis utilizing different methods (16). Estimates are derived from data from screening programs in Italy (45), Denmark (46), and Norway and Sweden (47); a microsimulation model (48); analysis of incidence data from screening trials (Swedish Two-County and Gothenburg trials (46, 49) and the Malmo Trial (50)); and a Markov model with data from the Swedish Two-County trial and several screening programs (51). None of these studies provide estimates specific to United States populations. Rates of overdiagnosis vary from <1% (45, 46, 49) to 30% (47), with most between 1% to 10%. Estimates differ by outcome (invasive versus in situ breast cancer), by whether cases are incident or prevalent, and by age. Studies are too heterogeneous to combine statistically.
Few trials evaluate the effectiveness or harms of CBE in decreasing breast cancer mortality. In countries with widely practiced mammography screening, the utility of CBE rests on its additional contribution to mortality reduction. The Canadian National Breast Screening Study-2 (CNBSS-2) trial, comparing mammography with CBE versus CBE alone, showed no difference in mortality between these two approaches (52).
Three trials were designed to determine mortality outcomes using CBE as the primary screening approach in countries with limited healthcare resources and without mammography screening programs (Table 4). A randomized trial comparing CBE to no screening was conducted in the Philippines, however, due to poor community acceptance it was discontinued after one screening round and is inconclusive (53). Two randomized trials comparing CBE to no screening are ongoing in Egypt (54) and India (55).
In the pilot study for the Cairo Breast Screening Trial, the risk of undergoing a benign procedure after one round of CBE was 1.2% (30/2481) (54). Of the 138,392 women examined in the Philippines study, 3,479 had abnormal CBEs and 1,220 completed diagnostic workups (53). Of these women, 34 (3%) had malignant cancers, 563 (46%) had no detectable abnormalities, and 623 (51%) underwent biopsies that were benign.
Preliminary results from trials of BSE in Russia and Shanghai were reviewed for the 2002 report (2), and final results have since been published (Table 4) (18, 56, 57). The impact of BSE on all-cause mortality in St. Petersburg, Russia, a community without routine mammography screening, was evaluated in a trial meeting criteria for fair quality (18, 56, 57). Despite a significant increase in the number of breast cancers detected when BSE instruction was provided, there was no reduction in all-cause mortality (relative risk 1.07; 95% CI 0.88 to 1.29) (18). A good-quality randomized trial conducted in Shanghai, China indicated breast cancer rates of 6.5/1,000 for women instructed in BSE and 6.7/1,000 for controls after 11 years of follow-up (58). The numbers of women who died from breast cancer were equal in both groups (135/132,979 and 131/133,085, respectively; relative risk 1.03; 95% CI 0.81 to 1.31). Published meta-analyses of BSE randomized trials (59-61) and non-randomized studies (59-61) also indicate no significant differences in breast cancer mortality between BSE and control groups.
In the Russian (18) and Shanghai (58) trials, more women randomized to BSE had benign biopsies than women in control groups (Russian relative risk 2.05; 95% CI 1.80 to 2.33; Shanghai relative risk 1.57; 95% CI 1.48 to 1.68). A retrospective cohort study of 27,421 women over the age of 40 in the United States indicated that those performing more frequent or longer duration BSEs were more likely to have diagnostic mammograms or ultrasounds, compared to women with less frequent and shorter BSEs (62). Contrary to the Russian and Shanghai studies, there was no significant association between BSE and biopsy rates in this study.
Table 5 summarizes the evidence for this review. Note that breast cancer mortality benefits from randomized controlled trials of screening are based on estimates of women invited to screening, whereas harms are based on data of women actually screened.
Trials of mammography screening for women age 39 to 49 indicate a statistically significant 15% reduction in breast cancer mortality for women randomized to screening versus those not. This translates to a number needed to invite for screening to prevent one breast cancer death of 1,904 (95% CrI 929 to 6,378). These results are similar to those for women age 50 to 59, but less than women age 60 to 69. For women age 70 and older, results from the Swedish Two-County trial of women age 70 to 74 indicate no mortality reduction. However, these results are limited by including only a small number of women from a single population. Interpreting trial results by age requires caution, because, except for the Age trial, age-specific results are sub-analyses of trials designed for different purposes.
Although the results of the meta-analysis have not changed markedly with the addition of the Age trial (29), its contribution to the evidence base is important. The Age trial is the only trial of mammography that specifically evaluates the effectiveness of screening women in their 40s. It is the largest trial and draws from a community population. It is the most recently performed trial, reflecting current screening, diagnostic, and treatment practices better than its predecessors, particularly those from the pre-tamoxifen era. As such, it is the most relevant trial. However, its results, while consistent with the meta-analysis in the direction of benefit, are not statistically significant. Also, its applicability to women in the United States is not clear in light of important differences between mammography screening practices in the United States and United Kingdom (63).
Harms of mammography screening have been identified, but their magnitude and impact are difficult to measure. The absolute level of radiation exposure and corresponding radiation risk from mammography is very low. Special considerations may be needed, however, for women exposed to additional radiation for other purposes, or women particularly susceptible to radiation and breast cancer such as BRCA mutation carriers. Patient adverse experiences, such as pain during procedures and anxiety and other psychological responses, are widely experienced, but appear to be transient and do not adversely influence future screening practices. This may vary for individual women. Estimates of the magnitude of overdiagnosis vary depending on the analytic approach used. These estimates are difficult to apply because, for individual women, it is not known which cancers will progress, how quickly cancers will advance, and expected lifetimes.
The effectiveness of CBE has not been proven in large, well designed trials. Current ongoing trials are limited to countries that do not provide routine mammography screening, restricting their applicability to the United States. Work ups for false positive findings subject women to additional imaging and procedures countering the potential benefits of this low-technology approach. For BSE, the Russian and Shanghai trials simultaneously showed no reductions in mortality and increased numbers of benign biopsies performed as a result of BSE instruction.
Although more information is available to determine the benefits and harms of routine breast cancer screening in average-risk women, questions remain unanswered. The least amount of data is available for women over age 70, a rapidly growing population in the United States. Recent observational studies indicate that regular screening mammography among older women is associated with earlier stage disease (64, 65) and lower breast cancer mortality (65). For the many older women who might live another 20 to 30 years, breast cancer detection and early treatment could reduce morbidity as well as mortality, optimizing independence, function, quality of life, and costs of care in the final years.
Breast cancer is a continuum of entities, not just one disease, that needs to be taken into account when considering screening and treatment options and when balancing benefits and harms. None of the screening trials consider breast cancer this way. As diagnostic and treatment experiences become more individualized (66) and include patient preferences, it becomes even more difficult to characterize benefits and harms in a general way.
New technologies, such as digital mammography and MRI, are becoming widely used in the United States without definitive studies of their impact on screening. Consumer expectations that new technology is better than old may obscure potential adverse effects such as higher false positives and expense. No screening trials incorporating newer technology have been published, and estimates of benefits and harms in this report are based predominantly on studies of film mammography. There are no definitive studies of the appropriate interval for mammography screening, although trial data reflect screening intervals from 12 to 33 months.
Our meta-analysis of mammography screening trials indicates breast cancer mortality benefit for all age groups between age 39 to 69, with insufficient data for older women. False positive results are common in all age groups and lead to additional imaging and biopsies. Women age 40 to 49 experience the highest rate of additional imaging while their biopsy rate is lower than older women. Mammography screening at any age is a tradeoff of a continuum of benefits and harms. The ages at which this tradeoff becomes acceptable to individuals and to society are not clearly resolved by available evidence.
Mary Barton, MD, MPP served as Project Officer at the Agency for Healthcare Research & Quality (AHRQ), and Russ Harris, MD, MPH; Allen Dietrich, MD; Carol Loveland-Cherry, PhD, RN; Judith Ockene, PhD, MEd; and Bernadette Melnyk, PhD, RN, CPNP/NPP served as US Preventive Services Task Force leads for this project.
We thank the Breast Cancer Surveillance Consortium (BCSC) investigators, participating mammography facilities, and radiologists for the data used in this project. A list of the BCSC investigators and procedures for requesting BCSC data for research purposes are provided at: http://breastscreening.cancer.gov/. Patricia A. Carney, PhD, Steve Taplin, MD, Sebastien Haneuse, PhD, and Rod Walker, MS worked directly with the investigators.
Andrew Hamilton, MLS, MS conducted the literature searches, and Sarah Baird, MS, managed the bibliography at the Oregon Evidence-based Practice Center at the Oregon Health & Science University.
Grant Support This manuscript is based on research conducted by the Oregon Evidence-based Practice Center under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-02-0024). Support for Kari Tyne, MD was provided by the Veteran's Administration Women's Health Fellowship; and support for Arpana Naik, MD by the Oregon Health & Science University Department of Surgery in conjunction with the Human Investigators Program. Data collection for this some of this work was supported by the NCI-funded Breast Cancer Surveillance Consortium (BCSC) co-operative agreement (U01CA63740, U01CA86076, U01CA86082, U01CA63736, U01CA70013, U01CA69976, U01CA63731, U01CA70040). The collection of cancer incidence data used in this study was supported in part by several state public health departments and cancer registries throughout the United States. For a full description of these sources, please see: http://breastscreening.cancer.gov/work/acknowledgement.html.
Publisher's Disclaimer: Disclaimer: The findings and conclusions in this document are those of the authors, who are responsible for its content, and do not necessarily represent the views of AHRQ. No statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services.